Nantkwest (NASDAQ:NK) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Nantkwest (NASDAQ:NK) posted its quarterly earnings data on Tuesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.02, Fidelity Earnings reports. The business had revenue of $0.01 million during the quarter. Nantkwest had a negative net margin of 125,903.34% and a negative return on equity of 48.18%.

Shares of NASDAQ NK traded down $0.02 during trading hours on Thursday, hitting $1.09. 106,600 shares of the stock were exchanged, compared to its average volume of 320,897. The company has a debt-to-equity ratio of 0.08, a current ratio of 7.00 and a quick ratio of 7.00. The company’s 50 day moving average is $1.19 and its 200 day moving average is $1.18. The firm has a market capitalization of $106.17 million, a P/E ratio of -0.89 and a beta of 2.29. Nantkwest has a one year low of $0.93 and a one year high of $4.10.

Separately, ValuEngine raised shares of Nantkwest from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Nantkwest Company Profile

NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

Recommended Story: How to calculate the annual rate of depreciation

Earnings History for Nantkwest (NASDAQ:NK)

Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with's FREE daily email newsletter.